An interventional study of comprehensive myopia control interventions in Myopia and Childhood Myopia, sponsored by Beijing Tongren Hospital. Recruiting at 1 site in China. Open to participants aged 6 Years to 16 Years. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Beijing Tongren Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Myopia by Beijing Tongren Hospital — 11 open to participants now, 12 under way, none of them phase 3. Myopia · Beijing Tongren Hospital.
Among the 22 studies in Myopia by Beijing Tongren Hospital, this one is the 3rd largest by planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2025, is one of 14 with no phase, reaches primary completion later than 9 of the 11 other live ones, and was the 22nd registered.
1,163 studies on the registry are indexed under Myopia; 227 are open to participants now.
Browse Myopia studies →11 of the 22 studies in Myopia by Beijing Tongren Hospital are open now, in 1 country. Recruiting first, the newest first:
Beijing Tongren Hospital · Sites in China
Healthy volunteers
Beijing Tongren Hospital · Sites in China
Ages 6–14 · Healthy volunteers
Beijing Tongren Hospital · Sites in China
Ages 6–9 · Healthy volunteers
Beijing Tongren Hospital · Sites in China
Ages 7–18 · Healthy volunteers
Beijing Tongren Hospital · Sites in China
Ages 6–12 · Healthy volunteers
By country, each count listing its studies:
Of the 120 Myopia studies recruiting now, 19 (16%) set no upper age limit and 100 (83%) stop at 75 or younger; 84 take children under 18; 52 take healthy volunteers.
This study: 6 Years to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 79 across 927 interventional studies indexed under Myopia.
Median enrollment 120 across the 17 interventional studies, 2,000 across the 5 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Beijing Tongren Hospital is the lead sponsor of 165 studies on the registry; 55 are open to participants now.
4 of the studies in Myopia by Beijing Tongren Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07724210Beijing Tongren HospitalEffectiveness of Digital Defocus Vision Training With Low-Concentration Atropine on the Prevention and Control of Myopia in Children: A Clinical Study | 2026-12-31 |
| NCT05786586Beijing Tongren Hospital650nm Low-level Red-light for Myopia Control and Prevention in Children | 2026-12-31 |
| NCT07412678Beijing Tongren HospitalEvaluation of the Efficacy of Red Light in Adult Patients With High and Extreme Myopia | 2027-03-11 |
| NCT07946094Beijing Tongren HospitalEvaluation of the Effect of Comprehensive Myopia Control Interventions on Myopia Prevention and Control | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 22 studies in Myopia by Beijing Tongren Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a single-center, single-arm, open-label interventional study to evaluate the efficacy of a comprehensive myopia-control regimen in delaying axial elongation and myopia progression in children aged 6-16 years. (Principal investigator: Zhenfei Yang from the Rehabilitation Hospital Affiliated to the National Research Center for Rehabilitation Technical Aids ). The regimen combines five components: (1) myopia-control spectacle lenses incorporating defocus design and Diffusion Optics Technology (DOT); (2) reading-writing glasses that optically relocate near targets to a virtual distance, reducing accommodative lag; (3) nutritional supplements (DHA/EPA, anthocyanins, astaxanthin, vitamin D3 and lutein); (4) repeated low-level red-light (RLRL, 650 nm) therapy; and (5) a distance-viewing device that projects near images to distance. A total of 300 children with myopia will be enrolled and followed for 12 months. The primary outcomes are the change in axial length and the change in cycloplegic spherical equivalent refraction from baseline to 12 months. Safety is monitored throughout by recording adverse events.
Rationale: Myopia prevalence in children is rising globally. Single interventions such as defocus spectacle lenses can slow myopia progression by approximately 40%; reading-writing glasses and distance-viewing devices reduce accommodative lag by optically relocating near targets to distance; nutritional supplements may improve choroidal blood supply and scleral oxygenation, thereby increasing scleral resistance to elongation; and repeated low-level red-light (RLRL) therapy at 650 nm may activate mitochondrial cytochrome c oxidase, enhance retinal pigment epithelium energy metabolism and promote dopamine release, inhibiting axial elongation. This study evaluates whether a combination of these approaches yields better myopia-control efficacy than single measures.
Design and procedures: Eligible children aged 6-16 years with myopia will receive the combined regimen for 12 months, including myopia-control spectacle lenses (defocus + DOT), reading-writing glasses for near work, daily nutritional supplements (DHA/EPA, anthocyanins, astaxanthin, vitamin D3, lutein), RLRL sessions (650 nm, per device instructions), and a distance-viewing device during study-related near tasks. Follow-up visits include ocular examinations, axial length measurement, and cycloplegic refraction. Adverse events are recorded and reported to the institutional ethics committee.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive the combined regimen consisting of the five interventions listed below for 12 months
Other: comprehensive myopia control interventions
spectacle lenses
Other: comprehensive myopia control interventions
Participants receive the combined regimen consisting of the five interventions listed below for 12 months
Change in axial length from baseline to 12 months
Axial length measured by optical biometry (IOL Master) at baseline and at 12 months; the change (mm) over 12 months is the primary measure of myopia-control efficacy.
Time frame: Baseline and 12 months
Started Aug 2025 (actual). Primary completion is estimated for Nov 2027, 27 months after the start.
Of 200 non-industry interventional studies with no phase under Myopia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 27 months is close to that.
Counting every sponsor, half of 434 studies reached it within 14 months; a quarter within 3 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.